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Abstract: 
On April 12, 2018, 41 GPCR researchers gathered at the Freie Universität Berlin, 
Germany. The purpose of the 1st Belin Symposium for Interdisciplinary GPCR 
research was to bring together research groups from various scientific disciplines 
based in Berlin and Potsdam who work on GPCRs. The meeting addressed mainly 
young researchers (i.e. advanced PhD students, Post-Docs and young group 
leaders) who presented their research in talks and poster sessions. The symposium 
provided a forum to discuss common questions in GPCR biology with researchers 
who address the same question from different angles. The meeting was an excellent 
venue for networking on the young researcher level and encouraged future 
interdisciplinary research in Berlin. 
 
Main text: 
G protein-coupled receptors (GPCRs) form the largest class of cell-membrane 
receptors and continue to be one of the important drug target classes1. Since the 
advent of the “crystallization era” about 10 years ago the field has made a quantum 
leap forward towards understanding the complex biology of GPCR activation and 
signaling2. However, fairly soon after a plethora of different structures including 
inactive and active receptors as well as receptor-G protein-complexes were 
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published, it became clear that high-resolution structures are not sufficient to explain 
the complex nature of GPCR biology2. Therefore, besides crystallography, the field 
uses a broad toolbox of biophysical, computational and pharmacological methods 
which allow capturing the inherent dynamics of GPCRs3 and are suitable to 
understand in more detail current hot topics in GPCR biology: i.e. allosteric 
modulation4,5, biased signaling6 and polypharmacology to name a few7. The latter 
aspects have attracted a lot of interest in drug discovery as they may open up novel 
strategies to modulate GPCR function more succinctly8. In addition to studying 
GPCRs on the atomic and molecular level, a lot of effort is put into translation of the 
novel in vitro findings into in vivo settings and disease models9. The growing 
understanding of the complexity of GPCR signaling requires to address major 
research questions from different angles spanning disciplines as diverse as 
biochemisty, biophysics, computational biology, pharmacology, cell biology and in 
vivo models. A highly interdisciplinary approach to pursue this avenue has proven 
valuable in many cases and may be the strategy of choice for the next generation of 
scientists10. 
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Figure 1: The participants of the 1st Berlin Symposium for Interdisciplinary GPCR 
research. In the middle of the first row: the organizers Dr. Marcel Bermudez (FU 
Berlin) and Dr. Andreas Bock (MDC).  
 
At the 1st Berlin Symposium for Interdisciplinary GPCR research which took place on 
April 12, 2018, a group of 41 junior scientists convened at the Institute for Pharmacy 
of the Freie Universität Berlin, Germany (Figure 1). The group was composed of 
researchers from the Freie Universität Berlin, the Charité-Universitätsmedizin Berlin, 
the Max-Delbrueck-Center for Molecular Medicine, the Leibniz Institute for Molecular 
Pharmacology, the German Center for Neurodegenerative Diseases (DZNE) Berlin 
and the Fraunhofer Institute for Cell Therapy and Immunology Potsdam-Golm. The 
participants represented a mélange of scientific disciplines with strong expertise in 
medical biophysics including X-ray crystallography and Cryo-EM complemented by 
pharmacology, computational biology and advanced microscopy. In addition to the 
groups with a stronger in vitro focus, a large party of in vivo-oriented and clinical 
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scientists came from disciplines such as anesthesiology, cardiology and vascular 
medicine, immunology, neuroscience and endocrinology.  
Scientific highlights of the meeting included novel strategies to express and produce 
large quantities of GPCRs in various hosts11 or by using eukaryotic cell-free protein 
synthesis12 (Michal Szczepek, Patrick Scheerer lab, Charité-Universitätsmedizin and 
Anna Zemella, Stefan Kubick lab, Fraunhofer IZI, Potsdam-Golm). Large-scale 
purification is necessary to conduct crystallization trials to capture atomic-resolution 
snapshots of different GPCR states and to perform biophysical experiments to study 
GPCR dynamics. In addition to heterotrimeric G proteins, β-arrestins are considered 
as important downstream signaling proteins of GPCRs. However, how GPCRs 
activate arrestins has not been understood. Very recent data have revealed that 
arrestins can be activated independently by both the receptors’ transmembrane core 
and the C-terminus. This has important implications for biased arresing signaling13 
(Martha Sommer, Charité-Universitätsmedizin). The design of novel GPCR agonists 
with limited side effects has attracted much interest over the last years. Two talks 
given at the symposium focused on this aspect. Researchers from the Chaité have 
recently succeded in developing an analgesic which targets µ-opioid receptors 
specifically in pathologic tissue in the periphery. This novel pH-sensitive fentanyl 
derivative appears to be an effective analgesic but is endowed with less side effects 
such as respiratory depression and obstipation which are commonly associated with 
classical opioidergic painkillers14 (Viola Spahn, Christoph Stein lab, Charité-
Universitätsmedizin). Another strategy in GPCR drug discovery is to develop biased 
ligands which favor one pathway over others. In vascular disease it may be valuable 
to design G-protein-biased ligands (Till Althoff, Charité-Universitätsmedizin). In 
addition to the above-mentioned aspects, compartmentalized GPCR signaling15 
(Andreas Bock, Martin Lohse lab, MDC), implications of GPCR trafficking on cellular 
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aging (Arthur Gibert, Ralf Schülein lab, FMP), strategies to use GPCR internalization 
to overcome defects of hormone transport (Sarah Paisdzior, Heike Biebermann lab, 
Charité-Universitätsmedizin), and the impact of cannabinoid receptor signaling in 
cortical neuron signaling were discussed (Alexander Stumpf, Dietmar Schmitz lab, 
DZNE Berlin). The topic of allosteric modulation of GPCRs was presented 
highlighting the development of negative allosteric modulators for TSH receptors 
(Patrick Marcinkowski, Gerd Krause lab, FMP). Focusing on cutting-edge technology, 
high-end (super-resolution) microscopy methods and their application to study 
various aspects of GPCR oligomerization, trafficking and signaling were discussed16 
(Paolo Annibale, Martin Lohse lab, MDC).  
The meeting was the first of its kind to concentrate the entire GPCR expertise 
available in Berlin and outskirts with a strong focus on junior scientists. The 
participants presented their research in talks and poster sessions. The heterogeneity 
of the group provided the possibility to discuss one’s own research with scientists 
from completely different fields. This not only inspired the researchers to pursue new 
ideas but also fostered interdisciplinarity.  
 
 
 
 
 
 
 
 
Figure 2: Word cloud generated by all abstracts submitted by the participants 
highlighting the interdisciplinarity of the meeting.  
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In addition to the scientific focus of the meeting, the participants discussed about the 
pros and cons of interdisciplinary research at an early stage of a scientific career 
(Marcel Bermudez, Gerhard Wolber lab, FU Berlin). How interdisciplinary can a 
young researcher be? Despite the rather obvious fact that interdisciplinary research 
is a highly valuable approach to tackle large and complex research questions related 
to GPCR biology, it can also be a burden in terms of positioning oneself in the field. 
Pursuing a career in academia is often successful when people can be assigned to a 
specific topic which may be in contrast to being interdisciplinary. With regard to 
funding, interdisciplinary projects are usually more complex and require more time to 
be published. This is often difficult for young researchers as contract times are 
limited.  
In summary, the 1st Belin Symposium for Interdisciplinary GPCR research provided a 
forum to discuss interdisciplinary GPCR research within Berlin and a networking 
platform for junior scientist. Given the large variety of disciplines present and 
techniques available, Berlin stands out as a highly attractive and competitive 
environment for interdisciplinary GPCR research.  
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